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Abstract Hepatitis C virus (HCV) cannot be grown in vitro,
making biochemical identi¢cation of new drug targets especially
important. HCV p7 is a small hydrophobic protein of unknown
function, yet necessary for particle infectivity in related viruses
[Harada, T. et al., (2000) J. Virol. 74, 9498^9506]. We show
that p7 can be cross-linked in vivo as hexamers. Escherichia coli
expressed p7 fusion proteins also form hexamers in vitro. These
and HIS-tagged p7 function as calcium ion channels in black
lipid membranes. This activity is abrogated by Amantadine, a
compound that inhibits ion channels of in£uenza [Hay, A.J. et
al. (1985) EMBO J. 4, 3021^3024; Du¡, K.C. and Ashley,
R.H. (1992) Virology 190, 485^489] and has recently been
shown to be active in combination with current HCV therapies.
? 2002 Published by Elsevier Science B.V. on behalf of the
Federation of European Biochemical Societies.
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1. Introduction
Hepatitis C virus (HCV) is a major cause of chronic hep-
atitis, cirrhosis and hepatocellular carcinoma [4] and is now
the leading indication for liver replacement surgery in the
developed world. Most infections result in a chronic carrier
state and current therapies are expensive, poorly tolerated and
e¡ective in only 50% of cases. Of particular concern is the
emergence of viral resistance to these regimes [5,6].
HCV belongs to the Hepacivirinae genus of the family Fla-
viviridae [7]. The RNA genome is translated into a single
polyprotein, which is proteolytically processed [8]. The func-
tions of several of the viral proteins are poorly understood
and study of the virus is complicated by the inability to cul-
ture it in vitro. p7 is a small hydrophobic protein located
between the structural and non-structural regions of the poly-
protein [9,10]. It is predicted to comprise two membrane-span-
ning helices linked by a small charged loop, and recent studies
have con¢rmed that it is indeed membrane associated and
mostly located in the endoplasmic reticulum [11]. Character-
istics of p7 are reminiscent of a group of proteins known as
viroporins. These homo-oligomerise to form ion channels and
are frequently involved in virus assembly and/or release [12^
18]. Disruption of viroporin function frequently abrogates vi-
ral infectivity, rendering them suitable targets for antiviral
drug development.
2. Materials and methods
2.1. Generation of p7 expression constructs
The p7 sequence from the J4 infectious clone of HCV genotype 1B
[19] was ampli¢ed by polymerase chain reaction (PCR) using a proof-
reading polymerase (Vent, New England Biolabs) with speci¢c prim-
ers and introduced into the mammalian expression vector pCDNA3.1
(Invitrogen) giving the construct pCDNAp7, or the bacterial gluta-
thione-S-transferase (GST) fusion vector pGEX4T1 (Amersham Phar-
macia Biotech) to give pGEXp7. A 6-HIS tag was incorporated into
the forward primer to generate a HIS-p7 cassette, used to generate
pGEXHp7.
2.2. Protein cross-linking assay
HepG2 cells (2U105) were transfected by the BBS calcium phos-
phate method with 2 Wg pCDNAp7 or control vector. 48 h post-trans-
fection, cells were washed, scraped into phosphate-bu¡ered saline
(PBS) and split into two separate tubes, to one of which DSP (di-
thio-bis-succinimidyl proprionate, Pierce Endogen) was added to
1 mM ¢nal concentration and incubated at room temperature for
30 min. The reaction was quenched with 10 mM Tris^Cl pH 7.5,
and the cells lysed and subjected to non-reducing sodium dodecyl
sulphate^polyacrylamide gel electrophoresis (SDS^PAGE) with the
exception of one cross-linked sample that was adjusted to 100 mM
dithiothreitol (DTT). p7 was subsequently detected by immunoblot
using a mouse polyclonal antiserum raised against a peptide corre-
sponding to the N-terminal 13 residues of p7. For cross-linking of
puri¢ed HIS-p7 (see below), 3 Wg of protein in PBS in the presence of
unilamellar lipid vesicles was incubated with DSP as above. Immuno-
blotting was performed using a sheep polyclonal antiserum raised
against puri¢ed bacterially expressed GST-HIS-p7.
2.3. Transmission electron microscopy
50 ng protein was added to PBS in the presence or absence of
arti¢cially synthesised unilamellar vesicles or microsomal membranes
(Promega, UK) in a volume of 125 Wl. For immunogold labelling, a
molar equivalent of biotinylated anti-GST monoclonal antibody (Se-
rotech) was added along with a three-fold molar excess of strepta-
vidin-coated 10 nM gold particles (Sigma). Samples were prepared by
the Valentine technique. Brie£y, the diluted sample was adsorbed to
carbon ¢lm for 30 s. The carbon was then washed in water and
negatively stained for 1 min in 2% uranyl acetate and mounted
onto gold-plated copper grids. Electron micrographs were taken on
a Phillips CM10 microscope.
2.4. Expression and puri¢cation of protein from Escherichia coli
Expression of GST fusions was induced in the presence of 0.1 mM
IPTG (isopropyl L-D-thiogalactopyranoside) in E. coli DH5K. Protein
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was puri¢ed according to standard methods [20] and dialysed against
PBS (or methanol where appropriate for use in calcium-containing
electrolyte). HIS-p7 was generated by overnight cleavage with throm-
bin at 10 units/mg of fusion protein and separated by GSTrap1
(Amersham Pharmacia Biotech) chromatography followed by collec-
tion of the £ow-through after passing through a 10 000 MWt ¢lter
(Microsep, Pall life sciences).
2.5. Ion channel formation in BLM
Equivalent molar amounts of fusion protein or derivatives were
added to the trans chamber of a thoroughly cleaned BLM chamber
containing a bilayer comprised of an equimolar mixture of phospha-
tidyl serine and phosphatidyl ethanolamine. The two Ag/AgCl elec-
trodes were placed in a Faraday cage to minimise noise during current
recordings and connected to a computer via an AXON patch-clamp
¢ltered at 50 Hz, an ADC interface and a DAT recorder. AXON
pclamp software was utilised to record and analyse the traces. To
monitor the e¡ect of Amantadine (Aldrich) on the formation of ion
channels, 40 Wl of Amantadine (20 WM in methanol) was added to
both cis and trans compartments giving a ¢nal concentration of 1 WM.
The current traces showing blocking of ion channels were recorded
within 10 s after Amantadine injection. Traces shown are representa-
tive 10^15 s windows from over 10 min of readings obtained in each
experiment. Each experiment was performed at least twice with di¡er-
ent protein preparations.
3. Results
3.1. HCV p7 is able to homo-oligomerise in membranes
To determine whether p7 possesses the ability to oligomer-
ise we expressed the protein in the hepatoma cell line, HepG2,
and stabilised higher order assemblages in living cells using a
lipid-soluble, cleavable cross-linking reagent, DSP. Total cel-
lular protein was analysed and p7 detected by immunoblotting
with an anti-p7 polyclonal antiserum (Fig. 1A, left-hand pan-
el). In cross-linked samples a band migrating at 42 kDa was
reproducibly observed which was absent from controls. Fur-
thermore, the 42 kDa band was not seen in reducing condi-
tions which cleaved DSP, indicating the presence of a hexame-
ric form of p7 stabilised by the cross-linking reagent.
Monomeric p7 from cell lysates transferred poorly, if at all,
to the trapping membrane. In addition, HIS-p7 (see below)
formed hexamers in vitro in the presence of DSP (Fig. 1A,
right-hand panel) as well as dimers, suggesting that hexameric
p7 assembles via an interaction between three such intermedi-
ates. The bands at 26 and 35 kDa represent trace contami-
nants of GST and GST-HIS-p7 respectively as assessed by
blotting with an anti-GST antibody (data not shown).
High yields of p7 were obtained by expression as a GST
fusion in E. coli. Fusion proteins or GST alone were examined
by transmission electron microscopy (TEM) following nega-
tive staining with uranyl acetate in the presence or absence of
lipids. GST-p7 formed ring structures at high frequency in the
presence of lipid (Fig. 1B) and also sporadically in aqueous
solution (data not shown). These structures were not observed
in the absence of GST-p7, or in the presence of GST alone
(data not shown), indicating that ring formation was solely
due to the p7 component of the fusion protein. Immunogold
labelling con¢rmed that the rings comprised GST moieties on
the outside surrounding an electron dense core of approxi-
6
Fig. 1. Hexamerisation of HCV p7. A: Protein from transiently
transfected HepG2 hepatoma cells or recombinant HIS-p7 was
cross-linked using the compound DSP (Pierce Endogen) and immu-
noblotted with an anti-p7 polyclonal serum (see Section 2). Left-
hand panel, lanes 1, mock transfected cells ; 2, mock transfected
cells+DSP; 3, pCDNA3.1 transfected cells (control vector);
4, pCDNA3.1 transfected cells+DSP; 5, pCDNAp7 transfected
cells; 6, pCDNAp7 transfected cells+DTT; 7, pCDNAp7 trans-
fected cells+DSP; 8, pCDNAp7 transfected cells+DSP+DTT. Right-
hand panel, lanes 1, 3 Wg bovine serum albumin (BSA); 2, 3 Wg
HIS-p7; 3, 3 Wg HIS-p7+DSP. B: GST fusions of p7 analysed by
TEM in the presence of microsomal membranes (panels 1^6) or ar-
ti¢cially synthesised unilamellar vesicles (panels 7^13). Panels 9^13
show protein immunolabelled with 10 nm gold particles. Scale bar
represents 10 nm. C: SDS^PAGE of puri¢ed GST fusion proteins
showing stabilisation following introduction of 6-HIS linker between
GST and p7 components of fusion proteins. Lanes 1, GST; 2, GST-
p7; 3, GST-HIS-p7. D: TEM of GST-HIS-p7 with immunogold la-
belling. Scale bar represents 10 nm. E: Panels 1^3, TEM of ring
structures obtained when cleaved HIS-p7 incubated with unilamellar
vesicles. Scale bar represents 5 nm. Panels 4 and 5 show planar and
side-on view of predicted p7 hexamer space-¢lling models, generated
using the ONO 6.2.2 programme.
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mately 4 nm diameter, the entire structure being 10 nm across.
The structures contained six subunits in each ring, consistent
with cross-linking studies.
Greatly improved yield and stability of the GST fusion
protein was achieved by introducing a 6-histidine tag into
the polylinker to produce GST-HIS-p7 (Fig. 1C). This fusion
product again formed 10 nm ring structures in the presence of
lipids (Fig. 1D) which were also immunogold labelled. Fur-
thermore, thrombin-induced cleavage to release the HIS-p7
portion of the fusion protein allowed generation of a near-
native p7 that also formed ring structures by TEM in the
presence of lipid (Fig. 1E) of 3^5 nm diameter. Computer
modelling was used to assess the likely stability and structure
of the p7 hexamer. The amino acids of p7 were mapped onto
a backbone of two K-helical domains of bacteriorhodopsin
and the orientation of each individual side chain modelled
by comparison with a database of protein crystal structures.
This allowed p7 amino acid side chains to be oriented relative
to neighbouring residues by assessing consensus bond rota-
tions and stoichiometric constraints (ONO 6.2.2 programme).
The predicted structure is a channel of 2.3 nm diameter com-
prising the amphipathic N-terminal helices of p7 forming a
channel, stabilised by the C-terminal helices interacting with
an adjacent p7sP N-terminal helix (Fig. 1E). The entire pre-
dicted structure measures 5.4 nm in diameter, consistent with
TEM studies. The side chains of the charged loop are pre-
dicted to project into the channel, likely forming a gate com-
ponent. This may explain why mutations of this region alone
in the related pestivirus bovine viral diarrhoea virus (BVDV)
are su⁄cient to abrogate infectivity [1].
3.2. HCV p7 forms ion channels in arti¢cial membranes
The ability of GST-p7 and derivatives to form ion channels
in vitro was investigated using a black lipid membrane con-
ductivity system in which ion channel activity is measured as a
£ow of current across an otherwise insulating membrane.
Representative traces from BLM experiments are shown. In
the absence of protein (Fig. 2A, top panel) negligible current
was observed indicating that the bilayer was intact; bilayer
formation itself was con¢rmed by capacitance measurements.
The addition of GST did not change the permeability of the
bilayer to potassium ions (Fig. 2A, middle panel). When GST-
p7 was added, however, transient current spikes were ob-
served (Fig. 2A, bottom panel), indicating that GST-p7
formed short-lived channels. Channel formation was voltage
dependent and no current £owed in the presence of protein
for trans-membrane voltages lower than 3120 mV (data not
shown). Furthermore, the ion current was directional (data
not shown), suggesting that GST-p7 inserted into the mem-
brane in a single orientation.
GST-HIS-p7 formed more e⁄cient ion channels than GST-
p7, both in frequency of channel opening and the amount of
current that £owed (Fig. 2B). As with GST-p7, the £ow of
current appeared to be directional (data not shown). Further-
more, GST-HIS-p7 displayed ion selectivity, for Ca2þ over
Kþ, as evidenced by greater burst activity and increased am-
plitude (Fig. 2C).
Cleaved HIS-p7 was used to examine the ion channel activ-
ity of p7 in the absence of a fusion protein partner. This
greatly increased channel activity (Fig. 3B) compared to the
parental GST-HIS-p7, indicating that the fusion partner had
been impeding ion channel formation. In accordance with this
observation, the trans-membrane voltage necessary to induce
channel formation by HIS-p7 was as little as 315 mV (data
not shown), though voltages were kept to a similar range for
consistency between experiments. In contrast to the GST fu-
sion proteins, with HIS-p7 the ion transport displayed no
directional dependence suggesting that it either inserted into
the membrane in both orientations, or that the channel itself
showed no directional dependence. HIS-p7 displayed an even
greater preference for Ca2þ than did GST-HIS-p7 (Fig. 3C).
3.3. HCV p7 ion channel formation is inhibited by Amantadine
Amantadine has been used clinically to treat in£uenza A
infection [21] and acts by inhibiting the M2 ion channel en-
coded by the virus [2,3,22^24]. As HIS-p7 had been shown in
this study to e⁄ciently form ion channels in a system very
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Fig. 2. Ion channel activity of GST fusions in black lipid membrane
systems. A: Ion channel activity of GST-p7. Top panel shows cur-
rent £ow across membrane bilayer in the absence of protein. Middle
panel shows trace obtained after the addition of GST. Bottom trace
shows burst activity obtained after the addition of GST-p7 to the
same chamber. B: Ion channel formation by GST-HIS-p7. Top
trace shows baseline in the absence of protein and bottom trace
shows current £ow upon addition of GST-HIS-p7. C: Ion channel
formation by GST-HIS-p7 with calcium-containing electrolyte (0.1 M
CaCl2) in place of potassium. Top trace shows baseline current in
the absence of protein and bottom trace shows burst activity upon
addition of GST-HIS-p7. Scales for time (horizontal axis) and cur-
rent (vertical axis) are shown for each trace.
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similar to that used to characterise M2 [3], we investigated the
e¡ect of Amantadine on p7 channel formation. Amantadine
was added to a ¢nal concentration of 1 WM; a concentration
previously shown to speci¢cally inhibit M2 in vitro [3]. The
high-e⁄ciency channel opening of HIS-p7 was abrogated by
the drug at this concentration (Fig. 3D). This e¡ect was spe-
ci¢c to the near-native HIS-p7 as GST-HIS-p7 was not af-
fected by the addition of Amantadine, even at concentrations
of 1 mM (data not shown).
4. Discussion
This is the ¢rst demonstration of a function for the p7
protein of HCV as a viral ion channel, most likely responsible
for the £ow of calcium ions from the endoplasmic reticulum
into the cytoplasm as has been observed for other viroporins
[14,16]. The equivalent protein of the related pestivirus,
BVDV, has been shown to be essential for the formation of
infectious virus particles [1], and taken together with the func-
tions of other viroporins, it is likely that HCV p7 acts at a
similar point in the virus life-cycle. Unfortunately, the current
lack of a HCV culture system that e⁄ciently produces infec-
tious virus particles prevents this hypothesis from being tested
and the e¡ect of Amantadine on viral replication in culture is
unknown, though Amantadine has been shown to inhibit viral
replication in patient PBMC cultured ex vivo [25]. In addition,
Amantadine has been used in clinical trials on HCV-infected
individuals and shows a signi¢cant degree of e⁄cacy, often
improving current therapeutic regimes comprising interferon
K and ribavirin [26^29]. Amantadine has been shown not to
a¡ect the functions of HCV protease, helicase, ATPase, poly-
merase, or internal ribosome entry in biochemical assays [30].
We propose that the e¡ects of Amantadine in such studies are,
therefore, due to inhibition of p7 function, making the search
for other p7 ion channel blocking compounds an attractive
new approach to anti-HCV chemotherapy.
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